key: cord-0843226-zowitb7k authors: Goldman, Ran D.; Marneni, Shashidhar R.; Seiler, Michelle; Brown, Julie C.; Klein, Eileen J.; Cotanda, Cristina Parra; Gelernter, Renana; Yan, Tyler D.; Hoeffe, Julia; Davis, Adrienne L.; Griffiths, Mark A.; Hall, Jeanine E.; Gualco, Gianluca; Mater, Ahmed; Manzano, Sergio; Thompson, Graham C.; Ahmed, Sara; Ali, Samina; Shimizu, Naoki; Ahmed, Sarah; Gaucher, Nathalie; Gianluca, Gualco; Goldman, Ran; Griffiths, Mark; Hansen, Matt; Katsuta, Tomohiro; Kelly, Christopher; Kozer, Eran; Shashidhar-R. Marneni,; Mistry, Rakesh; Parra, Cristina; Poonai, Naveen; Sheridan, David; Yue, Esther L. title: Caregivers’ willingness to accept expedited vaccine research during the COVID-19 pandemic – a cross sectional survey date: 2020-10-03 journal: Clin Ther DOI: 10.1016/j.clinthera.2020.09.012 sha: 86a77c8ef44d9e6d3de2b0aafc4081e33a57a632 doc_id: 843226 cord_uid: zowitb7k Purpose To determine predictors associated with caregivers’ willingness to accept an accelerated regulatory process for Coronavirus disease 2019 (COVID-19) vaccine development. Methods An international cross-sectional survey of 2557 caregivers arriving with their children to 17 pediatric Emergency Departments (ED) across six countries from March 26 to June 30, 2020. Caregivers were asked to select one of four choices they agreed with the most regarding a proposed COVID-19 vaccine approval process, in addition to questions regarding demographics, the ED visit, and attitudes about COVID-19. Univariate analyses were conducted using the Mann-Whitney test for comparing non-normal continuous variables, independent t-test for comparing normally distributed continuous variables, and Chi-square or Fisher’s exact test for categorical variables. Variables of interest subsequently underwent a multivariable logistic regression analysis to determine independent factors associated with caregivers’ willingness to accept abridged COVID-19 vaccine development. A p-value less than 0.05 was considered significant. Findings Almost half (1101/2557; 43%) of caregivers reported that they are willing to accept less rigorous testing and post-research approval for a new COVID-19 vaccine. Independent factors associated with willingness to expedite COVID-19 vaccine research included children that were up-to-date on their vaccination schedule (Odds Ratio (OR) = 1.72, 95% Confidence Interval (CI) = 1.29-2.31), caregivers concerned that they had COVID-19 at the time of survey completion in the ED (OR = 1.1, 95% CI 1.05-1.16), and caregivers that intend to vaccinate their children against COVID-19 if a vaccine becomes available (OR = 1.84, 95% CI 1.54-2.21). Mothers completing the survey were less likely to approve changes in the vaccine development process (OR = 0.64, 95% CI = 0.53-0.78). Implications Less than half of caregivers in a global sample are willing to accept abbreviated vaccine testing during the COVID-19 pandemic. As part of an effort to increase acceptance and uptake of the new vaccine, especially in order to protect children, public health strategies and individual providers should understand caregivers’ attitudes towards approval of the vaccine and consult them appropriately. Over 100 different vaccine candidates have been developed since the genetic sequence for SARS-CoV-2, 31 the virus that causes coronavirus disease 2019 (COVID-19), was published in January 2020. [1] 32 Vaccination will be one of the most effective strategies in limiting the spread of the disease by 33 establishing higher levels of herd immunity and preventing repeated or continuous epidemics. the licensure process for vaccines has been explored in the past for other infectious diseases including 47 tuberculosis, [11] serogroup B meningococcal disease, [12] and Zika virus. [13] 48 In the United States (US), it was estimated that only two thirds of people would be willing to get a 49 COVID-19 vaccine [14] . Parental vaccine hesitancy is associated with safety concerns, [15] and positive 50 public opinion and trust in an expedited COVID-19 vaccine is paramount to its success. [16] 51 Understanding caregivers' willingness to accept an expedited vaccination approval process may help 52 inform public health authorities and support effective rollout of a future COVID-19 vaccination program. 53 The objective of this study was to determine caregiver perceptions and attitudes regarding vaccine 54 research regulations, in the midst of the COVID-19 pandemic. 55 Sample and procedures 57 This study is part of a larger COVID-19 Parental Attitude Study (COVIPAS) of caregivers presenting for 58 emergency care for their children during the era of COVID-19. Using posters placed in waiting areas and 59 patient rooms, as well as direct approach by healthcare team members, caregivers (mostly parents) of 60 children 0 to 18 years of age who arrived to 17 pediatric emergency departments (ED) in the US (Seattle, 61 Tacoma, Los Angeles, Dallas, Atlanta), Canada (Vancouver, Toronto, Saskatoon, Edmonton, Calgary), 62 Israel (Be'er Ya'akov), Japan (Tokyo), Spain (Barcelona), and Switzerland (Zurich, Bern, Geneva, 63 Bellinzona) were asked to take part in the survey. 64 For infectious control purposes, caregivers used their own electronic devices (e.g. smartphones, tablets) 65 to complete the survey by logging into a secure online platform based on REDCap metadata-driven 66 software (Vanderbilt University). Once a caregiver selected their study site, they provided consent for 67 participation in the online survey, as approved by each site's local Institutional Review Board (IRB). Five 68 IRBs (in Switzerland and Spain) provided a waiver of consent whereby responding to the survey was 69 considered consent to participate. 70 The survey tool was available in English, French, German, Spanish, Japanese, Italian, and Hebrew. While content validity for all items of the survey, including those presented in this report, was completed a 81 priori by 10 individuals representing the target group of caregivers and by 10 healthcare providers working in the ED environment who provided feedback that led to revisions and development of the 83 final survey. 84 We asked caregivers to answer the question: "It usually takes several months or years to perform 85 scientific studies before a vaccine/immunization is approved for use. Which one do you agree with" 86 followed by four choices: "In a pandemic (disease that spreads across the world) like Coronavirus 87 (COVID-19) there is no need to wait for the usual research process, a vaccine/immunization should be 88 approved immediately," "In a pandemic (disease that spreads across the world) like Coronavirus (COVID-89 19) vaccine/immunization research should be more limited than the usual approval process (for 90 example, limited to several hundred people) and then approved for everyone," "In a pandemic (disease 91 that spreads across the world) like Coronavirus (COVID-19) we still need all the same research as for 92 other vaccines/immunizations before approval," or "Other". 93 94 Data analysis 95 Basic descriptive statistics and frequencies were used to describe all variables, comparing survey data 96 from caregivers who would support abridged COVID-19 vaccine regulations and those that would not. 97 To determine which factors were significantly associated with the decision to agree to expedited 98 regulation processes, we used univariate analyses: Mann-Whitney test for comparing non-normal 99 continuous variables, independent t-test for comparing normally distributed continuous variables, and 100 Chi-square or Fisher's exact test for categorical variables. We then used a multivariable logistic 101 regression analysis to estimate the adjusted odds ratio of agreeing to abridged vaccine testing, using all 102 the variables that showed significance (p <0.1) in the univariate analysis and other variables of interest. 103 To compare caregiver concern of their child having COVID-19 (score 0-10) to willingness to expedited 104 regulations, we used the Mann-Whitney U test. All analyses were conducted with R version 3.5.1. A p-105 value less than 0.05 was considered statistically significant. 106 A total of 2785 surveys were completed online. Seventeen (0.6%) were excluded because they were 108 completed by patients or were incomplete. Table 1 provides demographic information for the caregivers 109 that completed the survey. We further excluded 159 (5.7%) surveys since the caregivers did not provide 110 an answer to whether they recommend a similar or faster approval process (n=107) or responded "other" with no description of reasoning (n=52). Another 52 (1.9%) surveys with "other" were excluded 112 since caregivers provided descriptions suggesting they are 'against vaccines in general' (n=19), 113 suggested they 'do not know enough about the subject to answer this question' (n=19), thought that 'all 114 vaccines need better testing processes' (n=6), that 'Coronavirus is not real/not as bad as media portrays 115 it' (n=6) or that science need to focus on 'cure rather than vaccine' (n=2). This resulted in a total of 2557 116 survey responses included in the currently described study. 117 For surveys included (Table 2) vaccine became available were more likely to accept shortening or changing the vaccine testing process 129 (both p<0.001). Additional factors associated with greater willingness to modify regulations included 130 older caregivers (p<0.001), caregivers who were concerned they themselves or their child had COVID-19 131 (both p<0.001) or influenza (p=0.011 and p<0.001, respectively) when visiting the ED, caregivers 132 concerned about their child missing school (p=0.03), and caregivers that consider physical and social 133 distancing a worthwhile action (p=0.009). Caregivers who reported that they lost income due to the 134 COVID-19 pandemic were more likely to prefer to maintain current regulations for vaccine research 135 (p=0.009). 136 In the multivariate logistic regression analysis (Table 3) potentially reflecting greater concern about transmitting the illness to their children, were more likely to 185 want a vaccine to be ready faster. Similarly, if caregivers said they were planning to vaccinate their 186 children against COVID-19 they were more comfortable with a faster testing and approval process for 187 that vaccine. 188 Our surveys took place during the peak of the COVID-19 pandemic (Mar-June 2020) with daily media 189 reports of thousands of deaths and rapid new discoveries about the illness. It is possible that fear of the 190 pandemic and its devastating consequences have shifted caregiver acceptance to less rigorous 191 regulation. Similarly, fear about the H1N1 illness was associated with increased H1N1 vaccine uptake. 192 [32, 33] Willingness to accept emergency vaccine preparation and production and change in risk/benefit 193 ratio due to high morbidity and mortality has been suggested as acceptable [11, 34] We found that caregivers of children up-to-date with their vaccinations are likely to want a more relaxed 201 COVID-19 vaccine approval process. We surmise that these families trust the medical system and a 202 rigorous testing and approving process, and have had positive experiences with vaccinations. 203 Additionally, during the pandemic, they are willing to accept an abridged process. Similar to our findings, 204 prior seasonal influenza vaccination experience was associated with H1N1 vaccine uptake. Our study has some limitations. First, the population of parents and other caregivers responding to the 217 survey is not representative of all caregivers in the six countries where the survey took place, as we 218 administered the survey in a hospital ED setting during the peak of COVID-19. ED access patterns by 219 caregivers may have been influenced by the pandemic, resulting in delayed or omitted visits due to stay-220 in-place orders by local governments, or children who may not have ordinarily presented to the ED but 221 did because their primary health care provider was unavailable. Moreover, not all parents completed 222 the survey and a few (2.5%) respondents were caregivers other than parents (e.g. grandparents) who 223 may not be the decision makers. Also, requiring an electronic device such as a smartphone or tablet to 224 complete the survey may have prohibited participation for some. The COVID-19 vaccine development landscape Rapid COVID-19 vaccine development The global impact of COVID-19 and strategies for 261 mitigation and suppression Developing Covid-19 Vaccines at Pandemic Speed SARS-CoV-2 vaccines: Status report The history of vaccines: Vaccine development, testing, 267 and regulation The clinical development process for a novel preventive vaccine: An overview BioNTech's coronavirus vaccine candidates get FDA's 'fast track' status The Globe and Mail Human challenge studies to accelerate Coronavirus vaccine 277 licensure How close are we to a vaccine for COVID-19? CBC News Novel licensure pathways for expeditious introduction of 281 new tuberculosis vaccines: A discussion of the adaptive licensure concept Fast tracking the vaccine licensure 284 process to control an epidemic of serogroup B meningococcal disease in New Zealand Demonstrating vaccine efectivness during a waning 287 epidemic: A WHO/NIH meeting report on approaches to development and licensure of Zika 288 vaccine candidates Fauci says COVID-19 vaccine may not get US to herd immunity if too many people 290 refuse to get it Vaccine hesitancy: an overview When a COVID-19 vaccine is ready, will we all be ready for it? Int Exploring Lessons Learned from a Century of Outbreaks: 298 Readiness for 2030 Covid-19: What do we know so far about a vaccine? Planning for a COVID-19 vaccination program National Institutes of Health. NIH launches clinical trials network to test COVID-19 vaccines and 307 other prevention tools Willingness to vaccinate children against influenza 311 after the Coronavirus Disease 2019 pandemic Factors associated with 314 refusal of childhood vaccines among parents of school-aged children: A case-control study Sometimes: loss aversion and the effect of 319 motivational biases Barriers of influenza vaccination intention 321 and behavior -A systematic review of influenza vaccine hesitancy Underlying factors 324 impacting vaccine hesitancy in high income countries: a review of qualitative studies Post-market safety warnings for drugs approved in Canada under the Notice of 327 Compliance with conditions policy The hazards of rapid approval of new drugs Expediting drug development for serious illness: Trade-offs between patient access 330 and certainty COVID-19: Regulatory landscape of medicinal and medical device products for 332 human use Factors in vaccination intention against the pandemic influenza A/H1N1. Eur 335 Likely uptake of swine and seasonal flu vaccines among 337 healthcare workers. A cross-sectional analysis of UK telephone survey data Vaccines in a hurry Omission bias and vaccine rejection by parents of healthy 341 children: Implications for the influenza A/H1N1 vaccination programme Coronavirus disease 2019 in children Multisystem Inflammatory Syndrome Related to COVID-19 in Previously Healthy Children and Adolescents in Acceptance of vaccinations in pandemic outbreaks: 350 A discrete choice experiment Striking a balance between risk and protection: fathers' attitudes and 352 practices toward child injury prevention Being a good mom: low-income, black single mothers negotiate 354 intensive mothers Has chronic illness 2736 scale (SD) ☒ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.☐The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:J o u r n a l P r e -p r o o f